Antibiotic-resistant bacterial infection is a serious threat to public health. Peptidoglycan biosynthesis is a well-established target for antibiotic development. MraY (phospho-MurNAc-pentapeptide translocase) catalyses the first and an essential membrane step of peptidoglycan biosynthesis. It is considered a very promising target for the development of new antibiotics, as many naturally occurring nucleoside inhibitors with antibacterial activity target this enzyme 1-4 . However, antibiotics targeting MraY have not been developed for clinical use, mainly owing to a lack of structural insight into inhibition of this enzyme. Here we present the crystal structure of MraY from Aquifex aeolicus (MraY AA ) in complex with its naturally occurring inhibitor, muraymycin D2 (MD2). We show that after binding MD2, MraY AA undergoes remarkably large conformational rearrangements near the active site, which lead to the formation of a nucleoside-binding pocket and a peptidebinding site. MD2 binds the nucleoside-binding pocket like a two-pronged plug inserting into a socket. Further interactions it makes in the adjacent peptide-binding site anchor MD2 to and enhance its affinity for MraY AA . Surprisingly, MD2 does not interact with three acidic residues or the Mg 2+ cofactor required for catalysis, suggesting that MD2 binds to MraY AA in a manner that overlaps with, but is distinct from, its natural substrate, UDP-MurNAcpentapeptide. We have determined the principles of MD2 binding to MraY AA , including how it avoids the need for pyrophosphate and sugar moieties, which are essential features for substrate binding. The conformational plasticity of MraY could be the reason that it is the target of many structurally distinct inhibitors. These findings can inform the design of new inhibitors targeting MraY as well as its paralogues, WecA and TarO.
Despite their promise, no antibacterial natural products that target MraY have been developed for clinical use, in part owing to a lack of structural information on MraY catalysis and inhibition. We carried out structural studies of MraY in complex with a naturally occurring inhibitor of MraY, muraymycin, which shows antibacterial effects against MRSA, VRE and Pseudomonas aeuruginosa, and S. aureus 11, [13] [14] [15] [16] [17] [18] . We used MD2 for our structural, enzymatic and biophysical studies 17 (Extended Data Fig. 1b ). The muraymycins are known to be competitive inhibitors for the natural substrate UM5A (ref. 14) . Unlike UM5A, the muraymycins do not have pyrophosphate and sugar moieties and have a 5-aminoribosyl group (Extended Data Fig. 1b ). Using a radiochemical transfer assay 19 , we determined the Michaelis constant (K m ) for UM5A with purified MraY AA to be ~190 μM (Extended Data Fig. 1c ), which is within the range of measured cellular UM5A concentrations 20 . MraY AA activity is markedly reduced after addition of 0.3 μM MD2 (Fig 1a) . Using isothermal titration calorimetry (ITC), we measured the dissociation constant (K d ) of MD2 for MraY AA to be ~20 nM ( Fig. 1b) . We generated crystals of MraY AA in the presence of MD2, which diffracted to 2.95 Å. Phasing was obtained by molecular replacement using the apoMraY AA structure (PDB code 4J72) with all 1 Department of Biochemistry, Duke University Medical Center, 303 Research Drive, Durham, North Carolina 27710, USA. 2 Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nihi-6, Kita-ku, Sapporo 060-0812, Japan. 3 
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the cytoplasmic loops and TM9b removed as a search model. The structure was refined to good statistics (R/R free = 0.247/0.261) (Extended Data Table 1 ).
MraY AA in complex with MD2 crystallizes as a dimer, as does apoMraY AA 21 . Each protomer contains ten transmembrane helices (TM1-TM10) and five cytoplasmic loops (loops A-E) ( Fig. 2a ). TM9 breaks into two helical fragments (TM9a and TM9b), and TM9b bends outward towards the membrane (Fig. 2b ). We previously outlined the active site as a cleft formed by the inner-leaflet membrane regions of TM3, TM4, TM5, TM8 and TM9b and cytoplasmic loops B, C, D and E. Many absolutely conserved polar/charged amino acid residues are localized in this cleft, including three catalytically critical acidic residues: Asp117, Asp118 and Asp265 ( Fig. 2a , c), which are conserved in the PNPT superfamily 1, 19, [21] [22] [23] . Asp265 interacts with Mg 2+ in the apoMraY AA structure, and Asp117 has been proposed to bind to the phosphate moiety of C 55 -P (refs 21, 22) . Situated in the active site cleft, the nucleoside portion of MD2 is inserted between loop C and D and the peptide portion interacts with TM9b and loop E ( Fig. 2c ). High sequence conservation is observed around the MD2-binding region in the active site ( Fig. 2d ). Notably, MD2 does not interact with any of the three catalytically critical acidic residues ( Fig. 2c and Extended Data Fig. 1d ).
MraY undergoes remarkable conformational rearrangements near the active site upon binding MD2 (Fig. 3 ). The amphipathic TM9b rotates away from the active site while loop E rearranges, packs against the hydrophilic part of TM9b (Extended Data Fig. 2 and Supplementary Video 1), and a helical segment of the conserved HHH motif (PXHHHXEXXG) extends 1, 21 . This TM9b-loop E rearrangement widens and reshapes the active site, allowing the peptidic moiety of MD2 to bind to the side of TM9b and loop E (Extended Data Fig. 3 ). The carboxy-terminal portion of TM5 and loop C unwinds (cyan, Fig. 3a , b) and loop D rearranges (magenta, Fig. 3a, b ), creating a pocket where the 5-aminoribosyl moiety and the uracil base of uridine interact ( Fig. 3d and Extended Data Fig. 4a -c). The concerted motions of TM5 and loops C and D lead to the rearrangement of loop A and part of TM1 (green, Fig. 3a, b ), although these regions do not appear to interact with MD2 directly. It is noteworthy that the amino acid residues interacting with the uracil base move large distances (5-17 Å) while the residues interacting with the 5-aminoribosyl moiety move shorter distances (Extended Data Fig. 4a -c and Supplementary Video 1). The active-site structural rearrangement leads to substantial changes in its electrostatic potential, including enlargement of the acidic milieu around the nucleoside-binding pocket, which may play a role in MD2 binding ( Fig. 3c, d) .
Developing nucleotide-sugar mimicking inhibitors for glycosyltransferases has been challenging largely owing to the difficulty of developing pyrophosphate mimics capable of cellular entry with high affinity for the target enzyme [24] [25] [26] [27] . MraY is a phosphoglycosyltransferase that shares a common nucleotide sugar substrate with glycosyltransferases. Nucleoside antibiotics targeting MraY have garnered additional interest because they can enter the cell with high affinity for MraY 24, 25, 28 . MD2 does not contain a pyrophosphate or sugar moiety and has a 5-aminoribosyl group, which was thought to mimic the pyrophosphate in the natural substrate UM5A (refs 23, 29) (Extended Data Fig. 1b ). To understand the principle of MD2 inhibition of MraY AA , we performed mutagenesis and measured the mutational effects on MD2 binding using ITC. Amino acid residues involved in binding MD2 were grouped based on the substructures with which they interact: (1) uracil (Lys70, Gly194, Asp196, Asn255 and Phe262); (2) 5-amino ribose (Thr75, Asn190, Asp193 and Gly264), and (3) peptidic side chain (Gln305, Ala321 and His325). We performed site-directed mutagenesis on the residues that form side-chain interactions with MD2 (Lys70, Thr75, Asn190, Asp193, Asp196, Asn255, Phe262, Gln305 and His325) ( Fig. 4 ). The MraY AA mutants that showed substantial enzymatic activity (Extended Data Fig. 5 ) were used for ITC experiments with MD2 (Extended Data Fig. 6 and Extended Data Table 2 ).
The affinity of MD2 for MraY AA was most perturbed with Asp193Asn and Phe262Ala, mutations that disrupt interactions with the 5-aminoribose and uracil moieties of MD2, respectively ( Fig. 4 , Extended Data Table 2 and Extended Data Fig. 6 ). Phe262 interacts 
with the uracil base via a π-π interaction ( Fig. 4 and Extended Data Fig. 4d ). When Phe262 is mutated to another aromatic amino acid, such as tryptophan, there is a smaller effect on the K d value relative to the alanine mutation, indicating the importance of this π-π interaction. Residue Asp193 makes side-chain interactions with the 5-amino ribose moiety of MD2 (Extended Data Fig. 4e ). Because the Asp193Ala mutant is nearly inactive (Extended Data Fig. 5b ), we used functionally competent Asp193Asn for ITC with MD2 (Extended Data Fig. 5a ). However, the heat associated with binding was too low to measure, suggesting that the Asp193Asn mutation greatly reduces the affinity of MD2 for MraY AA (Extended Data Fig. 6 ). This observation is consistent with previous studies indicating the antibacterial activity of MraY inhibitors with a 5-aminoribose is dependent on the amino group of that moiety 29, 30 . The Gln305Ala mutant exhibits a larger than fivefold increase in K d (Fig. 4 and Extended Data Table 2 ), indicating that the interactions formed by the peptidic moiety of MD2 contribute to the binding affinity. Asp193, Phe262 and Gln305 are absolutely conserved in MraY orthologues 21 . The results from the equilibrium binding experiments are consistent with the enzymatic inhibition experiments because the Phe262Ala mutation results in partial inhibition and the Asp193Asn mutant is not inhibited in the presence of 1 μM MD2 (Extended Data Fig. 5a ). We infer that MD2 and the natural substrate, UM5A, use different strategies for binding MraY. First, the three catalytically critical acidic residues, including the Mg 2+ -binding Asp265, do not participate in direct interactions with MD2 (Extended Data Fig. 1d ). Second, the Asp193Asn mutant remains functionally active, although it disrupts an interaction MraY makes with the 5-aminoribosyl group and affects the binding affinity of MD2 markedly (Extended Data Table 2 and Extended Data Fig. 6 ). This suggests the 5-amino ribosyl group does not function as a pyrophosphate mimic and instead forms interactions that are not present in or important for UM5A binding. If MD2 lacks a pyrophosphate mimic, it is unlikely that Mg 2+ has an important role in MD2 binding. To test this idea, we performed ITC in the absence of Mg 2+ and found that MD2 does not require Mg 2+ for MraY binding (Fig. 4c ). It is possible that the amino group of the 5-aminoribose mimics Mg 2+ and Asp193 interacts with Mg 2+ , as previously suggested 14 .
However, in such a case, we would expect Asp193Asn to be inactive. Furthermore, the amino group of the 5-aminoribose is not near the Asp265, which coordinates Mg 2+ in the apoMraY structure 21 .
In summary, the 5-aminoribosyl and uracil moieties of MD2 bind to the nucleoside-binding pocket like a two-pronged electrical plug inserts into a socket, and these interactions are the most critical for binding. The peptidic moiety also contributes to the binding energy by anchoring MD2 to MraY, probably contributing to its specificity for MraY. With the 5-aminoribose moiety of MD2 positioned as a second prong alongside uridine in the nucleoside binding site, MD2 binds to MraY with increased affinity, making the pyrophosphate and sugar moieties unnecessary for binding. To confirm the importance of the 5-aminoribosyl and uracil moieties of MD2, we synthesized 5-aminoribosyl-3-deoxy uridine 29 and found it retains substantial binding affinity for MraY AA (Fig. 4d ). Our structural and biochemical studies demonstrate the principles of MD2 inhibition of MraY and explain why MD2 does not require pyrophosphate and sugar moieties for binding, unlike the natural substrate, UM5A. This illustrates an example of nature circumventing a long-standing problem in chemical biology: developing a nucleotide-sugar-like inhibitor for glycosyltransferases [24] [25] [26] [27] . Finally, the large conformational arrangement observed in MraY indicates 
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No statistical methods were used to predetermine sample size. Crystallization. Wild-type MraY AA and mutants were expressed and purified as described 21 . All MraY AA bacterial expression plasmids were 10× histidine (His 10 )maltose binding protein (MBP) fusion constructs expressed in C41 (DE3) cells. The cells were lysed by microfluidizer and the protein was extracted from the crude lysate using 40 mM dodecyl-maltoside. The lysates were centrifuged to remove the insoluble fraction and the supernatant was applied to a Co 2+ -affinity column for purification. The His 10 -MBP tag was cleaved overnight by PreScission Protease and MraY AA was isolated by gel filtration using a Superdex 200 10/300 GL column in the presence of 5 mM n-decyl-β-d-maltopyranoside (DM), 150 mM NaCl, 20 mM Tris-HCl, pH 8.0, and 2 mM dithiothreitol (DTT). All purification steps were performed at 4 °C. After gel filtration, the protein was concentrated to 10 mg ml −1 (~250 μM) and MD2 was added to a final concentration of 400-500 μM before crystallization. Crystals were grown using sitting-drop vapour diffusion in the presence of 50 mM MgCl 2 , 40% PEG400, and 100 mM sodium cacodylate, pH 5.6. Crystals were harvested after 10-14 days and flash frozen in liquid nitrogen. Data collection and structure determination. X-ray data were collected at beamlines 22-ID-D and 24-ID-C at the Advanced Photon Source in Argonne National Laboratory at a wavelength of 1.0 Å and processed using iMosflm. The data were ellipsoidally truncated at 3.0 Å on the c axis and anisotropically scaled using the UCLA anisotropy diffraction server (http://services.mbi.ucla.edu/anisoscale/). Phases of the MD2 complex structures were solved by molecular replacement using PHASER 31 with a partial apoMraY AA structure (PDB code 4J72, TM9b and cytoplasmic loops removed) as the search model. The omit electron density peaks corresponding to MD2 were prominent from the beginning of the refinement. After the protein model was built, a simulated annealing omit map was generated and MD2 was modelled. PHENIX 32 and Coot 33 were used to refine the structure.
The final model has good geometry with 98.8%/1.2%/0.0% Ramachandran favoured/allowed/outliers. , and 500 nM (His325Ala). The mutant MraY AA enzymes Asn190Ala, Asp193Ala, and Asp196Ala were added to the reaction mixture at a final concentration of 500 nM. All wild-type and mutant MraY AA enzymes were purified as previously described 21 . Each reaction was initiated with the addition of enzyme and it was quenched with 20 μl of 6 M pyridinium acetate, pH 3.0. The radiolabelled product, [ 14 C]lipid I, was isolated from the hydrophilic substrate, [ 14 C]UM5A, with butanol extraction (200 μl). After vortexing (30 s) and centrifugation at 3,000g (5 min), the upper butanol phase was removed, added to 5 ml scintillation fluid (Fisher Chemical), and analysed using a liquid scintillation counting method (d.p.m.) for 14 C detection (Packard 2500 TR Liquid Scintillation Analyzer). Control reactions lacking enzyme and inhibitor were incubated, extracted and analysed following the same protocol described above and were used for background subtraction. Each reaction rate was calculated by converting the d.p.m. measured (with background subtraction) to moles of [ 14 C]lipid I formed using the specific radioactivity and dividing by the reaction time. All experiments were performed in triplicate (technical replicates). Chemical synthesis. MD2 was synthesized as published 17 . The MD2 analogue, 5-aminoribosyl 3-deoxyuridine, was synthesized as published 35 , with a minor modification as follows. In the coupling of the hexose with the ribose, we replaced 5-azido-5-deoxy-d-ribofuranosyl chloride 2,3-diacetate in the original procedure with a synthetically equivalent 5-azido-5-deoxy-2,3-O-(1-methylethylidene)-dribofuranosyl fluoride since the ribofuranosyl fluoride was previously prepared in our laboratory 36 . Except for this minor modification, our synthesis of the MD2 analogue was identical to the original synthesis 35 . ITC. Wild-type MraY AA and mutants (Lys70Ala, Thr75Ala, Asp193Asn, Asn255Ala, Phe262Ala, Phe262Trp, Gln305Ala and His325Ala) were purified as previously described 21 Interactions between MraY AA and MD2 are shown as dotted lines. It is noteworthy that residues interacting with the uridine moiety of MD2 move large distances (5-17 Å for residues Lys70, Asp196, Asn255 and Phe262), while the residues binding the 5-aminoribosyl group of MD2 (Thr75, Asn190 and Asp193) do not make large side-chain movements after MD2 binding. The uridine and 5-amino ribosyl groups of MD2 are circled. d, Interactions between the uracil base of MD2 (green) and the nucleoside-binding pocket of MraY AA . The uracil base forms H-bonds with side chains of Asn255, Asp196 and Lys70 and forms a π-π interaction with Phe262. d, The 5-aminoribosyl group of MD2 forms H-bond interactions with side chains of Thr75, Asn190 and Asp193, and the backbone amide of Gly264.
